Henkel; Bernd
Patent Applications and Registrations
Patent applications and USPTO patent grants for Henkel; Bernd.The latest application filed is for "method of preparing peptides comprising a lipophilically modified lysine side chain".
Company Profile
6.18.27
- Henkel; Bernd - Frankfurt am Main DE
- Henkel; Bernd - Hofheim DE
- Henkel; Bernd - Planegg DE
- Henkel; Bernd - Eppstein-Bremthal DE
Patent Activity
| Patent | Date |
|---|---|
| Capping of unprotected amino groups during peptide synthesis Grant 11,028,123 - Henkel , et al. June 8, 2 | 2021-06-08 |
| Method of preparing peptides comprising a lipophilically modified lysine side chain Grant 11,021,512 - Henkel , et al. June 1, 2 | 2021-06-01 |
| Exendin-4 derivatives as dual GLP1/glucagon agonists Grant 10,758,592 - Haack , et al. Sep | 2020-09-01 |
| Method Of Preparing Peptides Comprising A Lipophilically Modified Lysine Side Chain App 20200024304 - HENKEL; Bernd ; et al. | 2020-01-23 |
| Capping Of Unprotected Amino Groups During Peptide Synthesis App 20190330263 - Henkel; Bernd ; et al. | 2019-10-31 |
| Method For Cleavage Of Solid Phase-bound Peptides From The Solid Phase App 20190330266 - FIEDLER; Wolfgang ; et al. | 2019-10-31 |
| Synthesis of cyclic imide containing peptide products Grant 10,450,343 - Henkel Oc | 2019-10-22 |
| Functionalized Exendin-4 derivatives Grant 10,253,079 - Haack , et al. | 2019-04-09 |
| Synthesis of hydantoin containing peptide products Grant 10,087,221 - Henkel October 2, 2 | 2018-10-02 |
| Exendin-4 Derivatives As Dual Glp1/glucagon Agonists App 20180185450 - Haack; Torsten ; et al. | 2018-07-05 |
| Exendin-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists Grant 9,982,029 - Bossart , et al. May 29, 2 | 2018-05-29 |
| Exendin-4 derivatives as selective glucagon receptor agonists Grant 9,932,381 - Haack , et al. April 3, 2 | 2018-04-03 |
| Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists Grant 9,789,165 - Kadereit , et al. October 17, 2 | 2017-10-17 |
| Non-acylated exendin-4 peptide analogues Grant 9,750,788 - Kadereit , et al. September 5, 2 | 2017-09-05 |
| Dual GLP-1/GIP receptor agonists Grant 9,751,926 - Kadereit , et al. September 5, 2 | 2017-09-05 |
| Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists Grant 9,745,360 - Haack , et al. August 29, 2 | 2017-08-29 |
| Functionalized Exendin-4 Derivatives App 20170216406 - Haack; Torsten ; et al. | 2017-08-03 |
| Dual GLP-1/glucagon receptor agonists Grant 9,694,053 - Haack , et al. July 4, 2 | 2017-07-04 |
| Functionalized exendin-4 derivatives Grant 9,670,261 - Haack , et al. June 6, 2 | 2017-06-06 |
| Exendin-4 Peptide Analogues As Dual Glp-1/glucagon Receptor Agonists App 20170022260 - Haack; Torsten ; et al. | 2017-01-26 |
| Exendin-4 Derivatives as Selective Peptidic Dual GLP-1/Glucagon Receptor Agonists App 20170008944 - BOSSART; Martin ; et al. | 2017-01-12 |
| Synthesis of Hydantoin Containing Peptide Products App 20160289282 - Henkel; Bernd | 2016-10-06 |
| Synthesis of Cyclic Imide Containing Peptide Products App 20160289263 - Henkel; Bernd | 2016-10-06 |
| Exendin-4 Derivatives As Dual Glp1/glucagon Agonists App 20160220643 - Haack; Torsten ; et al. | 2016-08-04 |
| Exendin-4 Peptide Analogues As Dual Glp-1/glucagon Receptor Agonists App 20160168225 - Haack; Torsten ; et al. | 2016-06-16 |
| Exendin-4 derivatives as dual GLP1/glucagon agonists Grant 9,365,632 - Haack , et al. June 14, 2 | 2016-06-14 |
| Exendin-4 Derivatives as Selective Glucagon Receptor Agonists App 20150368311 - HAACK; Torsten ; et al. | 2015-12-24 |
| Exendin-4 peptide analogues Grant 9,181,305 - Haack , et al. November 10, 2 | 2015-11-10 |
| Dual GLP-1/Glucagon Receptor Agonists App 20150164997 - Haack; Torsten ; et al. | 2015-06-18 |
| Non-acylated Exendin-4 Peptide Analogues App 20150164996 - Kadereit; Dieter ; et al. | 2015-06-18 |
| Exendin-4 Peptide Analogues App 20150166625 - Haack; Torsten ; et al. | 2015-06-18 |
| Exendin-4 Peptide Analogues as Dual GLP-1/GIP Agonists App 20150164995 - Kadereit; Dieter ; et al. | 2015-06-18 |
| Dual GLP-1/GIP Receptor Agonists App 20150166627 - Kadereit; Dieter ; et al. | 2015-06-18 |
| Dual Glp1/gip Or Trigonal Glp1/gip/glucagon Agonists App 20140221281 - HAACK; Torsten ; et al. | 2014-08-07 |
| Exendin-4 Derivatives as dual GLP1/GIP or trigonal GLP1/GIP/Glucagon Agonists App 20140213513 - Haack; Torsten ; et al. | 2014-07-31 |
| Exendin-4 Derivatives App 20140206608 - Haack; Torsten ; et al. | 2014-07-24 |
| Functionalized Exendin-4 Derivatives App 20140206609 - Haack; Torsten ; et al. | 2014-07-24 |
| Exendin-4 Derivatives As Dual Glp1/glucagon Agonists App 20140100156 - HAACK; Torsten ; et al. | 2014-04-10 |
| Exedin-4 Peptide Analogues App 20130336893 - HAACK; Torsten ; et al. | 2013-12-19 |
| Tubulysin analogues Grant 7,816,377 - Domling , et al. October 19, 2 | 2010-10-19 |
| Macrocycles for the treatment of cancer Grant 7,807,710 - Richter , et al. October 5, 2 | 2010-10-05 |
| Novel Macrocycles for the Treatment of Cancer App 20070225265 - Richter; Wolfgang ; et al. | 2007-09-27 |
| Novel tubulysin analogues App 20050239713 - Domling, Alexander ; et al. | 2005-10-27 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 